Gilles Schang

Societé Générale Asset Management Alternative Investment/Private Equity (SGAM AI/PE) is the banking group's European asset management center for Private Equity. They are located in Paris-La Défense. SGAM AI/PE is a division of the Société Générale Asset Management, established in 2003, which is a subsidiary of the bank's Global Investment Management and Services division. The ultimate parent firm is the French financial institution Société Générale (PK: SCGLY), established in 1864. Nationalized at different intervals throughout their history, the bank is in the private sector since 1997. SGAM AI/PE is composed of three units: venture capital, expansion capital and buyout, and fund of funds. In addition to their Paris office, they are also present in London, Milan, Munich, Warsaw, Bucharest and Casablanca.

Amundi Private Equity Funds SA (Amundi PEF) is the private equity subsidiary of Amundi SA, itself a subsidiary of Crédit Agricole SA (XP: ACA) in France. Formerly known as CAAM-CI, founded in 1999 as CPR Private Equity, Amundi PEF was formed in 2009 by combining the Crédit Agricole and Société Générale asset management operations. The firm is headquartered in Paris and has additional offices in Bucharest, Cairo, Casablanca, Tunis and Warsaw. They invest in companies at all stages of development, providing institutional and individual investors with a wide spectrum of investment opportunities.

BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development.

IJENKO SA provides internet services. It offers software intelligence for internet availability through data analytics and machine learning to manage technology system adaptation. The firm also provides energy and communication services in developing consumer electronic brands for consumer eco-systems and distribution models. The company was founded by Serge Subiron and Eric Chareyron in 2008 and is headquartered in Boulogne-Billancourt, France.

Coldway SA manufactures and sells sanitary storage solutions to the healthcare, logistics, and food industries. Its products include stand-alone refrigerated container, refrigerated roll, and other related equipment such as ice and insulated boxes. The company was founded by Laurent Rigaud and Francis Kindbeiter in 2001 and is headquartered in Pia, France.

Picometrics SA manufactures Laser Induced Fluorescence (LIF) detectors for liquid separation analysis. Its products include ZETALIF Evolution, ZETALIF LED, and ZETALIF Discovery. The company's detectors have been used in the analysis of a range of molecules such as proteins, carbohydrates, alcohols, thiols, amines, aldehydes and ketones, organic acids, nucleotides as well as fluorescent pharmaceutical products and illicit drugs. The company was founded in 1998 and is headquartered in Toulouse, France.

Gloster Sante Europe SAS manufactures equipment and products for disinfection purposes. The company was founded by Henry-Louis Schwal on April 23, 1999 and is headquartered in Issy-les-Moulineaux, France.

Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC.